Investigational Drug Information for Huperzine A
✉ Email this page to a colleague
What is the development status for investigational drug Huperzine A?
Huperzine A is an investigational drug.
There have been 16 clinical trials for Huperzine A.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2019.
The most common disease conditions in clinical trials are Alzheimer Disease, Cognitive Dysfunction, and Cognition Disorders. The leading clinical trial sponsors are Supernus Pharmaceuticals, Inc., Biscayne Neurotherapeutics, Inc., and U.S. Army Medical Research and Development Command.
There are two hundred and forty US patents protecting this investigational drug and three international patents.
Summary for Huperzine A
| US Patents | 240 |
| International Patents | 3,707 |
| US Patent Applications | 1,934 |
| WIPO Patent Applications | 770 |
| Japanese Patent Applications | 283 |
| Clinical Trial Progress | Phase 2 (2019-11-01) |
| Vendors | 108 |
Recent Clinical Trials for Huperzine A
| Title | Sponsor | Phase |
|---|---|---|
| The Effect of Huperzine A Injection on Postoperative Cognitive Dysfunction in Patients With Aneurysmal Subarachnoid Hemorrhage: a Pilot Study | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 4 |
| The Effect of Huperzine A Injection on Postoperative Cognitive Dysfunction in Patients With Aneurysmal Subarachnoid Hemorrhage: a Pilot Study | Wanbangde Pharmaceutical Group Co., LTD | Phase 4 |
| Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy | Supernus Pharmaceuticals, Inc. | Phase 2 |
Clinical Trial Summary for Huperzine A
Top disease conditions for Huperzine A
Top clinical trial sponsors for Huperzine A
US Patents for Huperzine A
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Huperzine A | ⤷ Try a Trial | Heterocyclic flavone derivatives, compositions, and methods related thereto | Emory University (Atlanta, GA) | ⤷ Try a Trial |
| Huperzine A | ⤷ Try a Trial | Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery | Corium International, Inc. (Menlo Park, CA) | ⤷ Try a Trial |
| Huperzine A | ⤷ Try a Trial | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder | Axovant Sciences GmbH (Basel, CH) | ⤷ Try a Trial |
| Huperzine A | ⤷ Try a Trial | 2-amino-6-methy1-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,- 3-thiazol-4-yl amides | Pfizer Inc. (New York, NY) | ⤷ Try a Trial |
| Huperzine A | ⤷ Try a Trial | Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications | AKER BIOMARINE ANTARCTIC AS (Stamsund, NO) | ⤷ Try a Trial |
| Huperzine A | ⤷ Try a Trial | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease | Axovant Sciences GmbH (Basel, CH) | ⤷ Try a Trial |
| Huperzine A | ⤷ Try a Trial | Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors | Pfizer Inc. (New York, NY) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Huperzine A
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Huperzine A | China | CN104487429 | 2032-07-27 | ⤷ Try a Trial |
| Huperzine A | European Patent Office | EP2877461 | 2032-07-27 | ⤷ Try a Trial |
| Huperzine A | World Intellectual Property Organization (WIPO) | WO2014018741 | 2032-07-27 | ⤷ Try a Trial |
| Huperzine A | Australia | AU2017301928 | 2036-07-27 | ⤷ Try a Trial |
| Huperzine A | Australia | AU2017301929 | 2036-07-27 | ⤷ Try a Trial |
| Huperzine A | Australia | AU2017302305 | 2036-07-27 | ⤷ Try a Trial |
| Huperzine A | Australia | AU2017302306 | 2036-07-27 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
